Journal of Clinical Oncology
Articles in this Issue
Integrated assessment of cachexia, body composition, and patient-reported outcomes in unplanned hospitalizations of patients with metastatic cancer (PRO-HAND study).
12075 Background: Patients with metastatic cancer hospitalized for unplanned admissions represent a highly vulnerable popu...
Survival in de novo versus metachronous metastatic breast cancer across molecular subtypes: A large real-world, propensity-matched analysis.
e12756 Background: Metastatic breast cancer (MBC) may present as de novo metastatic disease (dnMBC) or as metachronous rec...
DLL3-targeted therapy with tarlatamab in small cell lung cancer across lines of therapy: A systematic review of prospective and randomized clinical trials.
e14525 Background: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatment options beyond first-l...
Outcomes and efficacy of neuroendoscopic resection of intraventricular tumors: A systematic review and meta-analysis.
e14107 Background: Intraventricular neoplasms predominantly comprise benign tumors that obstruct cerebrospinal fluid flow,...
Uniting providers across institutions to support osteosarcoma care: Insights from 64 cases reviewed through the MIB agents TURBO board.
e13540 Background: TURBO (Tumor Review Board for Osteosarcoma), launched in 2022 by MIB Agents Osteosarcoma Alliance, is a...
Implementation science insights from a community-embedded cervical cancer screening program integrating high-risk human papillomavirus DNA testing with non-communicable disease screening in rural South India.
1509 Background: The WHO Cervical Cancer Elimination Initiative recommends screening ≥70% of eligible women and linking ≥9...
Fluoropyrimidine-related cardiotoxicity in patients with <i>DPYD</i> variants: A real-world cohort study.
e24035 Background: Fluoropyrimidines are foundational agents in gastrointestinal oncology but can cause severe toxicity in...
Preferences and motivations for self-collection HPV testing among cervical cancer screening-eligible U.S. women: A nationally representative study.
e17528 Background: The United States Food and Drug Administration recently approved the human papillomavirus (HPV) self-co...
Obese patients with non-small cell lung carcinoma and the intratumor microbiome and immune microenvironment.
e20675 Background: Data that obesity is the primary driver of alterations of intratumor microbiota (IM) is accumulating. A...
AI-powered volumetric and radiomic MRI brain analysis for prognostication and treatment response patterns in ALK+ NSCLC brain metastases: Comparative outcomes of brigatinib versus crizotinib.
e20520 Background: Brigatinib (brig) has demonstrated improved intracranial disease control compared to crizotinib (criz)...
A phase I trial of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in metastatic or unresectable pancreatic ductal adenocarcinoma (PDAC).
e16410 Background: Interleukin-1 Receptor Associated Kinase -4 (IRAK4) drives pro-survival NF-kB signaling in PDAC. In pre...
Mesenteric approach during pancreaticoduodenectomy as modulator of CTC DNA dynamics in pancreatic cancer.
e16464 Background: In pancreatic ductal adenocarcinoma (PDAC), surgical manipulation may facilitate the intraoperative rel...
Investigating interactions between pharmaceutical industry and oncologists in Africa: A secondary analysis of ONCOTRUST-2 study.
9034 Background: Following the hypothesis-generating ONCOTRUST-1 study, ONCOlogy TRansparency Under Scrutiny and Tracking...
Career fulfillment and intent to leave among oncology physicians: A global survey.
9009 Background: Burnout among U.S. oncologists has risen from 34% (2013) to 59% (2023), with global estimates of 32–45%....
Causes of death in patients with lymphoplasmacytic lymphoma.
e19079 Background: Lymphoplasmacytic lymphoma (LPL) is an indolent type of B-cell non-Hodgkin lymphoma. In the majority of...
Malignant hemangiopericytoma: A National Cancer Database study of demographic and socioeconomic factors.
e22628 Background: Malignant hemangiopericytoma (HPC) is a rare and solitary fibrous tumor arising from pericytes surround...
Efficacy and safety of anlotinib and sintilimab combined with GEMOX in advanced combined hepatocellular-cholangiocarcinoma (cHCC-CCA): A prospective phase II study.
e16203 Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer with poor prognosi...
Integrative genomic profiling of Indian brain tumors: Prognostic markers and actionable therapeutic opportunities.
e14096 Background: Brain tumors are aggressive malignancies with substantial genetic heterogeneity, complicating prognosis...
An optimized machine learning model for overall survival prediction in brain metastasis patients using genomic mutation and copy number features.
e14002 Background: Cancer progression and patient survival are influenced by both tumor-intrinsic and microenvironmental f...
Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis.
3026 Background: Treatment options in China are limited for patients with late-line, HER2-expressing advanced solid tumors...
Association of GFPT2 expression with clinical outcomes in clear cell renal cell carcinoma.
e16543 Background: Progression of clear cell renal cell carcinoma (ccRCC) is driven in part by tumor microenvironment remo...
Optimal adjuvant therapy for early-stage cervical cancer (ESCC) with intermediate-risk factors: A target trial emulation of GOG-0263 based on the NCDB.
5539 Background: Optimal adjuvant therapy for early-stage cervical cancer (ESCC) patients with intermediate-risk factors r...
Integrating HER2-targeted antibody-drug conjugates into mucinous ovarian cancer treatment: A preclinical assesstment.
e17545 Background: Mucinous ovarian cancer (MOC) is a rare epithelial ovarian cancer. There are currently no systematic th...
Clinical trial participation among adolescents and young adults diagnosed with cancer in the United States (2004-2021).
1560 Background: Adolescents and young adults (AYAs, 15-39 years) have low historical participation in cancer clinical tri...
Safety, pharmacokinetic, and preliminary efficacy of SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): A phase 1 study.
8106 Background: SCLC and LCNEC are characterized by aggressive clinical courses and limited therapeutic options following...